• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions.全球综合安全评估监管格局:最新进展与未来方向。
Ther Innov Regul Sci. 2020 Mar;54(2):447-461. doi: 10.1007/s43441-019-00076-4. Epub 2020 Jan 6.
2
SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.用于有症状性玻璃体黄斑粘连的奥克裂纤酶的安全性概况:上市前和上市后经验的综合分析
Retina. 2015 Jun;35(6):1128-34. doi: 10.1097/IAE.0000000000000519.
3
Postmarketing Surveillance Studies-An Industry Perspective on Changing Global Requirements and Implications.上市后监测研究——行业对全球需求变化及影响的视角
Clin Ther. 2017 Apr;39(4):675-685. doi: 10.1016/j.clinthera.2017.03.011. Epub 2017 Apr 7.
4
A problem-oriented approach to safety issues in drug development and beyond.一种针对药物研发及其他领域安全问题的问题导向型方法。
Drug Saf. 2004;27(8):555-67. doi: 10.2165/00002018-200427080-00007.
5
Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.评估非有源植入式医疗器械与药物相比的安全性概况。
Drug Saf. 2017 Jan;40(1):37-47. doi: 10.1007/s40264-016-0474-1.
6
Interdisciplinary Safety Evaluation for Learning and Decision-Making.跨学科学习与决策安全评估
Ther Innov Regul Sci. 2021 Jul;55(4):705-716. doi: 10.1007/s43441-021-00268-x. Epub 2021 Mar 17.
7
The importance of cross-disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessments.跨学科科学参与在总体安全性评估定量程序开发中的重要性。
Pharm Stat. 2019 Oct;18(5):510-512. doi: 10.1002/pst.1949. Epub 2019 May 22.
8
The identification of benefit in medical intervention: an overview and suggestions for process.医学干预中获益的识别:概述与流程建议
Am J Ther. 2008 Sep-Oct;15(5):495-503. doi: 10.1097/MJT.0b013e31816b8fff.
9
Bridge the gap: The need for harmonized regulatory and ethical standards for postmarketing observational studies.弥合差距:上市后观察性研究需要统一的监管和道德标准。
Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1299-1306. doi: 10.1002/pds.4269. Epub 2017 Aug 16.
10
A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.药物安全监测入门:行业视角。第三部分:不良事件数据管理。
J Pharm Technol. 1992 Nov-Dec;8(6):259-73. doi: 10.1177/875512259200800608.

引用本文的文献

1
Aggregation of Adverse Event Terms for Signal Detection and Labeling in Clinical Trials.临床试验中用于信号检测和标签标注的不良事件术语汇总
Drug Saf. 2025 Feb 14. doi: 10.1007/s40264-025-01518-9.
2
Aggregate IND Safety Reporting for Smaller Companies and Programs.汇总小公司和项目的 IND 安全性报告。
Ther Innov Regul Sci. 2024 Mar;58(2):368-379. doi: 10.1007/s43441-023-00605-2. Epub 2024 Jan 8.
3
Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities.从美国经验看药物警戒的加强:现行做法与未来机遇
Drug Saf. 2021 Aug;44(8):843-852. doi: 10.1007/s40264-021-01078-8. Epub 2021 May 15.

全球综合安全评估监管格局:最新进展与未来方向。

Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions.

机构信息

Clinical Safety Statistics, Merck Research Laboratories, RY 34-A318, 126 E Lincoln Ave, Rahway, NJ, 07065-4607, USA.

Global Patient Safety, Eli Lilly and Company, Windlesham, UK.

出版信息

Ther Innov Regul Sci. 2020 Mar;54(2):447-461. doi: 10.1007/s43441-019-00076-4. Epub 2020 Jan 6.

DOI:10.1007/s43441-019-00076-4
PMID:32072595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7222952/
Abstract

Notwithstanding successful harmonization efforts, the global regulatory framework governing product safety is complex and continually evolving, as evidenced by additional regional guidance and regulations. In this regulatory review, we provide an overview from both global and regional perspectives. A historical perspective, with a focus on recent developments, enables identification of important long-term trends, such as a shift from single-case medical review of serious adverse events to an interdisciplinary evaluation of aggregate data for the purpose of judging product causality and informing benefit-risk assessments. We will show how these trends lead to opportunities for closer interdisciplinary collaboration, for bridging the gap between preand postmarketing surveillance, and for a more proactive determination of patient populations with a positive benefit-risk profile for product use. We will conclude by pointing to ongoing and future work that seeks to provide specific solutions for ongoing aggregate safety evaluation.

摘要

尽管已经进行了成功的协调努力,但全球产品安全监管框架仍然复杂且不断演变,这一点从额外的区域指导方针和法规中可以得到证明。在本次监管审查中,我们从全球和区域角度提供了概述。从历史角度出发,重点关注近期的发展情况,可以确定一些重要的长期趋势,例如,从对严重不良事件的单一案例医学审查转变为对汇总数据的跨学科评估,以判断产品因果关系并为利益风险评估提供信息。我们将展示这些趋势如何为更密切的跨学科合作、缩小上市前和上市后监测之间的差距,以及更积极地确定具有产品使用正利益风险特征的患者群体提供机会。最后,我们将指出正在进行和未来的工作,这些工作旨在为正在进行的汇总安全评估提供具体的解决方案。